Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Urticaria symbols : TEVJF save search
Urticaria Drugs Market size to grow by USD 1.31 billion from 2021 to 2026, Driven by the growth in incidence of urticaria - Technavio
Published: 2023-04-04 (Crawled : 22:00) - prnewswire.com
GLAXF | $20.2 -14.18% 510
|
Health Technology
|
| O: 1.79%
H: 3.07%
C: 3.07%
SNYNF | News | $92.116 -2.18% 2.3K
|
Health Technology
|
| O: 0.69%
H: 0.0%
C: 0.0%
NVSEF | News | $93.6375 6.88% 82K
|
Health Technology
|
| O: 1.57%
H: 1.01%
C: 0.96%
VTRS | $11.095 -0.22% -0.23% 6.1M
|
Health Technology
|
| O: -0.1%
H: 3.15%
C: 2.94%
NVS | News | $93.08 -0.13% 0.86% 1.2M
|
Health Technology
|
| O: 1.29%
H: 0.83%
C: 0.4%
GSK | $39.6 -0.88% 0.0% 2.8M
|
Health Technology
|
| O: 1.2%
H: 1.32%
C: 1.24%
SNY | News | $46.125 0.71% 0.7% 3.7M
|
Health Technology
|
| O: 1.58%
H: 0.0%
C: 0.0%
ALLK | $1.05 0.0% 340K
|
Health Technology
|
| O: -0.96%
H: 1.21%
C: -0.24%
urticaria growth market
USD 1.31 Bn growth for Urticaria Drugs Market through 2026: Analysing growth for Pharmaceuticals - Technavio
Published: 2022-09-29 (Crawled : 09:00) - prnewswire.com
GLAXF | $20.2 -14.18% 510
|
Health Technology
|
| O: -3.32%
H: 4.73%
C: 4.73%
SNYNF | News | $92.116 -2.18% 2.3K
|
Health Technology
|
| O: 0.22%
H: 0.33%
C: 0.33%
NVSEF | News | $93.6375 6.88% 82K
|
Health Technology
|
| O: 1.87%
H: 0.0%
C: 0.0%
VTRS | $11.095 -0.22% -0.23% 6.1M
|
Health Technology
|
| O: -1.26%
H: 0.7%
C: -0.23%
NVS | News | $93.08 -0.13% 0.86% 1.2M
|
Health Technology
|
| O: 0.17%
H: 1.1%
C: 0.16%
GSK | $39.6 -0.88% 0.0% 2.8M
|
Health Technology
|
| O: -0.14%
H: 0.53%
C: -0.2%
SNY | News | $46.125 0.71% 0.7% 3.7M
|
Health Technology
|
| O: -0.13%
H: 0.0%
C: 0.0%
ALLK | $1.05 0.0% 340K
|
Health Technology
|
| O: -2.77%
H: 2.14%
C: -0.18%
pharmaceuticals urticaria growth market
Late-breaking phase 3 data at 2022 AAAAI Annual Meeting show Dupixent® (dupilumab) significantly reduced itch and hives in patients with chronic spontaneous urticaria
Published: 2022-02-26 (Crawled : 20:20) - globenewswire.com
SNYNF | News | $92.116 -2.18% 2.3K
|
Health Technology
| Email alert
Add to watchlist
REGN | $901.27 0.8% 0.78% 470K
|
Health Technology
| Email alert
Add to watchlist
TEVJF | $12.37 -24.22% 380
|
Health Technology
| Email alert
Add to watchlist
SNY | News | $46.125 0.71% 0.7% 3.7M
|
Health Technology
| Email alert
Add to watchlist
dupixent urticaria phase 3 hiv
Update on ongoing Dupixent® (dupilumab) chronic spontaneous urticaria Phase 3 program
Published: 2022-02-18 (Crawled : 09:00) - biospace.com/
SNYNF | News | $92.116 -2.18% 2.3K
|
Health Technology
|
| O: -0.23%
H: 0.0%
C: -6.31%
SNY | News | $46.125 0.71% 0.7% 3.7M
|
Health Technology
|
| O: -0.47%
H: 0.77%
C: -0.23%
REGN | $901.27 0.8% 0.78% 470K
|
Health Technology
|
| O: -0.78%
H: 1.76%
C: -1.08%
dupixent ongoing program phase 3 urticaria
Regeneron and Sanofi Provide Update on Ongoing Dupixent® (dupilumab) Chronic Spontaneous Urticaria Phase 3 Program
Published: 2022-02-18 (Crawled : 07:00) - prnewswire.com
SNYNF | News | $92.116 -2.18% 2.3K
|
Health Technology
|
| O: -0.23%
H: 0.0%
C: -6.31%
SNY | News | $46.125 0.71% 0.7% 3.7M
|
Health Technology
|
| O: -0.47%
H: 0.77%
C: -0.23%
REGN | $901.27 0.8% 0.78% 470K
|
Health Technology
|
| O: -0.78%
H: 1.76%
C: -1.08%
dupixent ongoing program phase 3 urticaria
Gainers vs Losers
| 56% | 44% |
Top 10 Gainers
INVO | $1.76 131.58% 56.82% 230M
|
Health Technology
SINT | $0.0365 59.39% 37.26% 470M
|
Health Technology
WISA 4 | $9.19 50.66% 33.7% 65M
|
Electronic Technology
EDBL | News | $6.73 47.91% 32.39% 13M
|
GCTK | $0.715 36.27% 26.62% 640K
|
Manufacturing
TCON | $2.33 36.26% 26.61% 2M
|
Health Technology
TIRX | $0.48 6.43% 24.58% 4.8M
|
KZIA | $0.38 30.58% 23.42% 300K
|
Health Technology
VNDA | News | $5.23 29.14% 22.56% 24M
|
Health Technology
ATNF | $1.91 29.05% 22.51% 310K
|
Your saved searches
Save your searches and get alerts when important news are released.